Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, October 14, 2025
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Wednesday, October 8, 2025
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Friday, October 3, 2025
Eisai Highlights Breadth of Oncology Research at ESMO 2025
Monday, September 29, 2025
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
Wednesday, September 24, 2025
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
Wednesday, September 17, 2025
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
Friday, September 12, 2025
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Monday, September 8, 2025
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Thursday, September 4, 2025
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Wednesday, September 3, 2025
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: